[Meta-analysis of phase III studies with palonosetron in the prevention of vomiting induced by moderately emetogenic chemotherapy].
Di Maio
Massimo
M
Unità di Oncologia, Presidio Ospedaliero N. Giannettasio, Rossano.
Gallo
Ciro
C
Perrone
Francesco
F
D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D000077608:Aprepitant; D017326:Clinical Trials, Phase III as Topic; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007546:Isoquinolines / Q000627:therapeutic use*; D009025:Morpholines / Q000627:therapeutic use; D017294:Ondansetron / Q000627:therapeutic use; D000077924:Palonosetron; D011807:Quinolizines / Q000627:therapeutic use; D011812:Quinuclidines / Q000627:therapeutic use*; D012107:Research Design; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced* / Q000517:prevention & control*
D000932:Antiemetics; D000077608:Aprepitant; D017829:Granisetron; D007211:Indoles; D007546:Isoquinolines; D009025:Morpholines; D017294:Ondansetron; D000077924:Palonosetron; D011807:Quinolizines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077526:Tropisetron; C060344:dolasetron